SCHEMBL19088511

SCHEMBL19088511

CC(C)(C)[Si](C)(C)O[C@H](Cc1ccc(C2=CCOCC2)cc1)C(=O)OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 1/20 0.37
CTSC P53634 1/20 0.35
PIK3CD O00329 3/20 0.35
PIK3CA P42336 3/20 0.35
PIK3CB P42338 3/20 0.35
PIK3CG P48736 3/20 0.35
PIK3R1 P27986 2/20 0.35
PPARG P37231 4/20 0.34
PPARA Q07869 3/20 0.34
MAPK1 P28482 1/20 0.34
FABP7 O15540 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGA2B P08514 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25364300 0.87 CTSC (0.38) BRD4CTSCPPARGPPARA
SCHEMBL19066783 0.87 CTSC (0.38) BRD4CTSCPPARGPPARA
SCHEMBL23279516 0.86 PPARG (0.41) BRD4CTSCPIK3CDPIK3CAPIK3CB
SCHEMBL24297791 0.84 BRD4 (0.37) BRD4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL18407496 0.83 TBK1 (0.34) PPARGPPARAMEN1KMT2AITGB3
SCHEMBL29771333 0.81 PPARG (0.44) PPARGPPARA
SCHEMBL23279538 0.80 LTA4H (0.40) BRD4CTSCMAPK1FABP7MEN1
SCHEMBL18256350 0.80 LTA4H (0.40) BRD4CTSCMAPK1FABP7MEN1
SCHEMBL27408468 0.80 BRD4 (0.37) BRD4PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL19088501 0.79 AAK1 (0.36) BRD4CTSCPPARGPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018048-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2024-06-25 US disclosed
EP-3397638-B1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) 2023-08-23 EP disclosed
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2022-03-31 US disclosed
US-11230571-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2022-01-25 US disclosed
US-20190248840-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS Boehringer Ingelheim Animal Health USA Inc. (US) 2019-08-15 US disclosed
US-10344056-B2 Anthelmintic depsipeptide compounds Boehringer Ingelheim Animal Health USA Inc. (US) 2019-07-09 US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL INC. (US) 2017-08-17 US disclosed
WO-2017116702-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS MERIAL, INC. (US) 2017-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10344056-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP BRD4 1334/4885CTSC 9/4885PIK3CD 2119/4885
US-12018048-B2 Anthelmintic depsipeptide compounds VIP, DNPEP, DPEP1 BRD4 2833/4885CTSC 9/4885PIK3CD 2817/4885
US-20170233438-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP BRD4 1334/4885CTSC 9/4885PIK3CD 2119/4885
US-20220098241-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP BRD4 1334/4885CTSC 9/4885PIK3CD 2119/4885
US-20190248840-A1 ANTHELMINTIC DEPSIPEPTIDE COMPOUNDS VIP, PREP, DNPEP BRD4 1334/4885CTSC 9/4885PIK3CD 2119/4885
US-11230571-B2 Anthelmintic depsipeptide compounds VIP, PREP, DNPEP BRD4 1334/4885CTSC 9/4885PIK3CD 2119/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.